GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.
Mixing topical solutions like Morr F 10% (Minoxidil) and L'Oreal Seryoxyl (Stemoxydine) before application may not reduce their effectiveness. The goal is to apply treatments all at once instead of multiple times a day.
The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.
Users discuss whether Koshine reduces sebum and scalp itchiness. Some report reduced sebum and seborrheic dermatitis, while others debate the effectiveness of anti-androgens like RU58841 for hair loss.
The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.
The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.
The user experienced positive hair regrowth using 5% topical minoxidil daily and 1mg finasteride daily but had to stop finasteride due to side effects like depression, anxiety, and gynecomastia. They are considering alternatives like topical finasteride or dutasteride and are currently using only topical minoxidil.
The user reported using 1.2 mg finasteride and 3 mg minoxidil, experiencing initial shedding and increased hair growth on knuckles, arms, and forehead. They did not notice any significant side effects.
Combining stemoxydine with topical minoxidil for hair loss treatment. Users discuss application order and effectiveness, with some skepticism about stemoxydine's benefits.
Korean minoxidil is preferred over Foligain due to its non-greasy, fast-drying formula that lacks propylene glycol, making it more pleasant to use. The user has been using minoxidil for over two years and finasteride for about ten months, but it's unclear how much the Korean minoxidil has contributed to their results.
Minoxidil should be applied first, allowed to dry, then emu oil can be applied. Emu oil is recommended for daily use, but it may not need to be washed off daily.
The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.
The user is exploring topical treatments AHK-CU and GHK-CU for hair loss, avoiding Minoxidil and prescription medications. They believe their hair loss is not genetic but caused by Accutane, and are considering products like Neurogan and Bloom by Fleur.
A user with mild psoriasis on the scalp is using finasteride, topical minoxidil, and dermarolling for hair loss but plans to stop minoxidil on the crown due to psoriasis aggravation. Suggestions include switching to a lipid-based minoxidil, using Ketoconazole shampoo, or trying oral minoxidil.
The user experienced significant hair regrowth using 1mg oral finasteride daily and recently added minoxidil 5% to address remaining gaps. They reported no significant side effects, attributing any perceived changes to weight fluctuations rather than the medication.
The conversation discusses using minoxidil foam as a solvent for topical finasteride. Ingredients of minoxidil foam include butane, cetyl alcohol, glycerin, and purified water.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
The user experienced positive results using oral minoxidil and finasteride chewables for hair loss, with no significant side effects. They noted new hair growth and shared their routine, which includes diet changes and weightlifting.
Switching from minoxidil foam to topical solution and considering adding caffeine, melatonin, or cetirizine. Currently using 2.5mg oral minoxidil and 1mg oral finasteride, planning to ask for 0.5mg oral dutasteride and 5mg oral minoxidil.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
The conversation discusses the use of topical minoxidil for hair loss and the potential benefits of taking a Minoxidil Response Test to determine enzyme activity related to its effectiveness. Some users have considered or tried alternatives like oral minoxidil or tretinoin, with mixed experiences regarding side effects and effectiveness.
The user experienced heart palpitations after starting oral minoxidil and wonders if it's due to increased cardio activities or the medication. Other users suggest it might be a side effect of minoxidil, with some sharing similar experiences, and recommend consulting a doctor.